Institute of Immunology and Immunotherapy Immunology is at the forefront of medical research and we are among the leaders of this exciting, fast-evolving field.
News AI used to predict future flares of ulcerative colitis activity Ulcerative colitis assessment could be improved after new research shows that an AI model could predict flare-ups and complications after reading biopsies.
QS World University Subject Rankings released for 2023 University of Birmingham rises 30 places to be joint 62nd in the world for Life Sciences and Medicine.
03 March 2023 New research to understand immune responses against COVID-19 vaccination Study received £2.8m of Department of Health and Social Care funding to find out if testing can identify which immunosuppressed people remain at greatest risk.
03 March 2023 AI used to predict future flares of ulcerative colitis activity Ulcerative colitis assessment could be improved after new research shows that an AI model could predict flare-ups and complications after reading biopsies.
21 February 2023 £1 million award for BactiVac Network to continue supporting development of bacterial vaccines Bacterial infections kill over 7 million people each year and the development of new and better vaccines will reduce this devastating burden of disease.
15 February 2023 Efficacy of BCG vaccine in reducing COPD exacerbations funded for £1.8M University of Birmingham researchers have received a £1.8M grant by the NIHR EME Programme investigating BCG vaccine efficacy in reducing COPD exacerbations.
08 February 2023 Leukaemia trial testing vaccine strategies to combat immune suppression The IMPROVE clinical trial is testing whether vaccine timing can help clinically vulnerable people build antibodies
03 February 2023 Immunocompromised patients remain at higher risk of COVID-19 death in hospital Patients had 44% higher risk of death in hospital compared to those with healthy immune system function
16 January 2023 Experimental cancer therapy research continues at Birmingham New and innovative ways to detect and treat cancer being trialled at Birmingham are to receive renewed funding from Cancer Research UK and the NIHR.